8-K: Avalo Therapeutics Highlights AVTX-009 Potential in Hidradenitis Suppurativa with Investor Presentation

Avalo Therapeutics released an updated investor presentation highlighting the potential of AVTX-009, an anti-IL-1 mAb, for treating Hidradenitis Suppurativa (HS) and other autoimmune diseases.

Summary

• Avalo Therapeutics is focused on developing AVTX-009, a highly potent anti-IL-1 monoclonal antibody, for the treatment of Hidradenitis Suppurativa (HS).
• The company anticipates topline results for AVTX-009 in HS by 2026.
• Avalo secured up to $185 million in PIPE financing in March 2024, providing a cash runway into 2027.
• AVTX-009 has shown high potency with a Kd of <3 pM and a half-life of approximately 19 days, potentially allowing for less frequent dosing.
• The company believes that IL-1 is a key driver in the pathophysiology of HS, supported by clinical evidence from other anti-IL-1 therapies.
• A Phase 2 study for AVTX-009 in HS is planned with a primary endpoint of HiSCR75 at 16 weeks.
• The global HS market is estimated to be multi-billion dollar, with a significant unmet need for effective treatments.
• Avalo is also exploring potential additional indications for AVTX-009 in other autoimmune diseases, such as Inflammatory Bowel Disease (IBD).

Sentiment

Score: 7

Explanation: The document presents a positive outlook for AVTX-009, highlighting its potential and the large market opportunity. However, there are inherent risks associated with clinical trials and the competitive landscape, which temper the overall sentiment.

Positives

• AVTX-009 has a high potency and favorable half-life, potentially leading to improved efficacy and convenient dosing.
• The company has secured significant funding, providing a cash runway into 2027.
• Clinical evidence suggests that IL-1 is a key driver in HS, supporting the development of AVTX-009.
• The HS market is large and underserved, presenting a significant commercial opportunity.
• AVTX-009 has shown excellent tolerability and safety in previous trials.
• The company has an experienced management team with a proven track record in late-stage immunology development.

Negatives

• Some clinical evidence suggests that anti-IL-1 therapy may not be effective in HS, which could pose a risk to the success of AVTX-009.
• The Phase 2 study for AVTX-009 is not expected to produce results until 2026, which is a long time for investors to wait.
• The company is reliant on the success of a single drug candidate, AVTX-009, which increases the risk profile.

Risks

• The success of AVTX-009 is dependent on positive results from the Phase 2 clinical trial.
• There is a risk that the clinical trial may not meet its primary endpoint.
• Regulatory approvals are not guaranteed and may be delayed.
• The company faces competition from other companies developing treatments for HS.
• General economic and market risks, including those caused by the war in Ukraine and the Middle East, could impact the company's performance.

Future Outlook

Avalo plans to advance AVTX-009 through clinical trials, with topline results expected in 2026, and explore its potential in other autoimmune diseases. The company also intends to evaluate combination approaches with lutikizumab and Skyrizi in Crohn's disease.

Management Comments

• Avalo believes AVTX-009 has a high probability of success in HS.
• AbbVie plans to evaluate lutikizumab, a dual-variable-domain interleukin (IL) 1/1 antagonist, as monotherapy in UC and in combination with SKYRIZI in Crohn's.
• AbbVie believes lutikizumab has the potential to be used in combinations to provide transformational levels of efficacy in IBD.

Industry Context

The focus on IL-1 inhibition aligns with broader trends in immunology, where targeting specific cytokines is becoming increasingly common. The development of AVTX-009 is part of a larger effort to address unmet needs in inflammatory and autoimmune diseases, with several companies exploring similar approaches.

Comparison to Industry Standards

• The presentation compares AVTX-009 to other IL-1 inhibitors like canakinumab and gevokizumab, highlighting its superior potency in vitro.
• The company references the lutikizumab trial (NCT05139602) as validation of IL-1 targeting in HS, noting that its efficacy was comparable to other HS therapies despite a more severe patient population.
• The presentation also discusses the failure of bermekimab in two Phase 2 trials (NCT04019041 and NCT04988308) to demonstrate efficacy in HS, suggesting that monospecific IL-1 inhibition may be more effective than bispecific approaches.
• The company notes that Novartis' MAS825, a bispecific inhibitor of IL-1 and IL-18, showed positive results in a Phase 2 study (NCT03827798), but that IL-18 is not strongly implicated in the pathophysiology of HS.

Stakeholder Impact

• Shareholders may benefit from the potential success of AVTX-009 and the company's growth.
• Patients with HS may have access to a new treatment option if AVTX-009 is successful.
• Employees may benefit from the company's growth and success.

Next Steps

• Avalo plans to initiate a Phase 2 study for AVTX-009 in Hidradenitis Suppurativa.
• The company will continue to explore potential additional indications for AVTX-009 in other autoimmune diseases.
• Avalo will evaluate combination approaches with lutikizumab and Skyrizi in Crohn's disease.

Key Dates

Keywords

AVTX-009, Hidradenitis Suppurativa, HS, Anti-IL-1 mAb, Autoimmune Diseases, Inflammatory Bowel Disease, IL-1, Clinical Trial, Biologics, Phase 2, PIPE Financing